AstraZeneca beats forecasts in Q3, reaffirms full-year guidance

Investing.com -- AstraZeneca reported stronger-than-expected third-quarter results on Thursday, driven by robust sales across its oncology, cardiovascular and renal portfolios. The company kept its full-year outlook unchanged.

Core earnings rose 12% to $2.38 per share for the three months ended September 30, topping expectations of $2.29 per share. Revenue grew 10% at constant exchange rates to $15.19 billion, also ahead of the $14.79 billion consensus from a company-provided survey.

Core operating profit increased 13% to $4.99 billion.

Looking ahead, AstraZeneca continues to project full-year revenue growth in the high single digits and core earnings per share growth in the low double digits.

“The strong underlying momentum across our business through the first nine months of the year sets us up well to sustain growth through 2026 and has us on track to deliver our 2030 ambition,” Chief Executive Pascal Soriot said.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• BofA downgrades Amrize to underperform, cuts price target on slower growth outlook
• Premarket movers: Dell, GitLab surge and MongoDB tumbles